A phase Ib dose-finding, pharmacokinetic study of the focal adhesion kinase inhibitor GSK2256098 and trametinib in patients with advanced solid tumours

BACKGROUND: Combined focal adhesion kinase (FAK) and MEK inhibition may provide greater anticancer effect than FAK monotherapy. METHODS: This dose-finding phase Ib study (adaptive 3 + 3 design) determined the maximum tolerated dose (MTD) of trametinib and the FAK inhibitor GSK2256098 in combination....

Descripción completa

Detalles Bibliográficos
Autores principales: Mak, Gabriel, Soria, Jean-Charles, Blagden, Sarah P., Plummer, Ruth, Fleming, Ronald A., Nebot, Noelia, Zhang, Jianping, Mazumdar, Jolly, Rogan, Debra, Gazzah, Anas, Rizzuto, Ivana, Greystoke, Alastair, Yan, Li, Tolson, Jerry, Auger, Kurt R., Arkenau, Hendrik-Tobias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6735221/
https://www.ncbi.nlm.nih.gov/pubmed/30992546
http://dx.doi.org/10.1038/s41416-019-0452-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6735221/
https://www.ncbi.nlm.nih.gov/pubmed/30992546
http://dx.doi.org/10.1038/s41416-019-0452-3

Ejemplares similares